Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ

Background Controversy exists regarding the optimal negative margin width for ductal carcinoma in situ (DCIS) treated with breast-conserving surgery and whole-breast irradiation (WBRT). Methods A multidisciplinary consensus panel used a meta-analysis of margin width and ipsilateral breast tumor recurrence (IBTR) from a systematic review of 20 studies including 7883 patients and other published literature as the evidence base for consensus. Results Negative margins halve the risk of IBTR compared with positive margins defined as ink on DCIS. A 2 mm margin minimizes the risk of IBTR compared with smaller negative margins. More widely clear margins do not significantly decrease IBTR compared with 2 mm margins. Negative margins less than 2 mm alone are not an indication for mastectomy, and factors known to impact rates of IBTR should be considered in determining the need for re-excision. Conclusion The use of a 2 mm margin as the standard for an adequate margin in DCIS treated with WBRT is associated with low rates of IBTR and has the potential to decrease re-excision rates, improve cosmetic outcome, and decrease health care costs. Clinical judgment should be used in determining the need for further surgery in patients with negative margins < 2 mm.

[1]  M. Morrow,et al.  Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years , 2015, Annals of Surgical Oncology.

[2]  E. Hwang,et al.  Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. , 2015, Journal of the National Cancer Institute.

[3]  J. Cuzick,et al.  A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial , 2010, British Journal of Cancer.

[4]  P. Bult,et al.  Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. , 1994, Seminars in diagnostic pathology.

[5]  R. Gray,et al.  Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Martino,et al.  The influence of margin width on local control of ductal carcinoma in situ of the breast. , 1999, The New England journal of medicine.

[7]  Y. Li,et al.  The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study. , 2015, International journal of surgery.

[8]  G. Noël,et al.  [Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853]. , 2001, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[9]  Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. , 2009, JAMA.

[10]  J. Peterse,et al.  Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Barbara L. Smith,et al.  RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  George W. Sledge,et al.  A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast , 2013, Journal of the National Cancer Institute.

[13]  L. Holmberg,et al.  SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening , 2006, Acta oncologica.

[14]  J. Cuzick,et al.  Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial , 2010, The Lancet. Oncology.

[15]  M. Morrow,et al.  Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ: Analysis of 2996 Women Treated With Breast-conserving Surgery for 30 Years. , 2015, Annals of surgery.

[16]  S. Shak,et al.  A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone , 2015, Breast Cancer Research and Treatment.

[17]  D G Altman,et al.  Bayesians and frequentists , 1998, BMJ.

[18]  B. Haffty,et al.  Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. , 2008, International journal of radiation oncology, biology, physics.

[19]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[20]  M. Morrow,et al.  Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Irwig,et al.  The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis , 2016, Annals of Surgical Oncology.

[22]  Benjamin D. Smith,et al.  Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. , 2011, International journal of radiation oncology, biology, physics.

[23]  E. van Limbergen,et al.  Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. , 2015, The Lancet. Oncology.

[24]  Seema A Khan,et al.  Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer , 2014, Annals of Surgical Oncology.

[25]  J. Houghton Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial , 2003, The Lancet.

[26]  H. Bartelink,et al.  Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Julian,et al.  Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. , 2011, Journal of the National Cancer Institute.

[28]  Ping Sun,et al.  Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. , 2015, JAMA oncology.

[29]  S. Schnitt,et al.  The relationship between shaved margin and inked margin status in breast excision specimens , 1997, Cancer.

[30]  Reshma Jagsi,et al.  What is an Adequate Margin for Breast-Conserving Surgery? Surgeon Attitudes and Correlates , 2010, Annals of Surgical Oncology.

[31]  Seema A Khan,et al.  Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Lawrence B Marks,et al.  Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). , 2009, Journal of the American College of Surgeons.

[33]  R. Peto,et al.  Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. , 2010, Journal of the National Cancer Institute. Monographs.

[34]  D. Carter Margins of "lumpectomy" for breast cancer. , 1986, Human pathology.

[35]  J. Costantino,et al.  Pathologic findings from the national surgical adjuvant breast project (NSABP) protocol B‐17: Intraductal carcinoma (ductal carcinoma in situ) , 2006 .

[36]  Barbara L. Smith,et al.  Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS) , 2013, Breast Cancer Research and Treatment.